Comparison of Microfluidic Platforms for the Enrichment of Circulating Tumor Cells in Breast Cancer Patients

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 2022 Sep 8

PMID 36074219

Authors

Constantin Sajdik

Eva Schuster

Barbara Holzer

Michael Krainer

Christine Deutschmann

Stefan Peter

Maximilian Marhold

Robert Zeillinger

Eva Obermayr

Affiliations

Soon will be listed here.

Abstract

Purpose: Circulating tumor cells (CTCs) hold promise to be a non-invasive measurable biomarker in all cancer stages. Because the analysis of CTCs is still a technical challenge, we compared different types of microfluidic enrichment protocols to isolate these rare cells from the blood.

Methods: Blood samples from patients with early and metastatic breast cancer (BC) were processed using the microfluidic Parsortix® technology employing (i) a single-step cell separation using the standard GEN3D6.5 microfluidic cassette, (ii) a two-step separation with an upfront pre-enrichment, and (iii) a two-step separation with a different type of cassette. In the enriched cells, the gene expression levels of CTC-related transcripts were assessed using quantitative real-time PCR (qPCR) by Taqman® and Lightcycler (LC) technology.

Results: 23/60 (38.3%) BC samples were assigned as positive due to the presence of at least one gene marker beyond the threshold level. The prevalence of epithelial markers was significantly higher in metastatic compared to early BC (EpCAM: 31.3% vs. 7.3%; CK19: 21.1% vs. 2.4%). A high level of concordance was observed between CK19 assessed by Taqman® and LC technology, and for detection of the BC-specific gene SCGB2A2. An upfront pre-enrichment resulted in lower leukocyte contamination, at the cost of fewer tumor cells captured.

Conclusion: The Parsortix® system offers both reasonable recovery of tumor cells and depletion of contaminating leukocytes when the single-step separation using the GEN3D6.5 cassette is employed. Careful selection of suitable markers and cut-off thresholds is an essential point for the subsequent molecular analysis of the enriched cells.

Citing Articles

Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer.

Welsch E, Bonstingl L, Holzer B, Schuster E, Weiss E, Zaharie A Clin Exp Metastasis. 2024; 41(6):937-945.

PMID: 39305397 PMC: 11607046. DOI: 10.1007/s10585-024-10313-2.

Comparison of RNA Marker Panels for Circulating Tumor Cells and Evaluation of Their Prognostic Relevance in Breast Cancer.

Welsch E, Schuster E, Krainer M, Marhold M, Bartsch R, Fischer M Cancers (Basel). 2023; 15(4).

PMID: 36831613 PMC: 9954525. DOI: 10.3390/cancers15041271.

References

Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F . A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. Cell Physiol Biochem. 2017; 44(2):594-606. DOI: 10.1159/000485115. View

Stathopoulou A, Ntoulia M, Perraki M, Apostolaki S, Mavroudis D, Malamos N . A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Int J Cancer. 2006; 119(7):1654-9. DOI: 10.1002/ijc.22017. View

Josefsson A, Larsson K, Freyhult E, Damber J, Welen K . Gene Expression Alterations during Development of Castration-Resistant Prostate Cancer Are Detected in Circulating Tumor Cells. Cancers (Basel). 2019; 12(1). PMC: 7016678. DOI: 10.3390/cancers12010039. View

Bredemeier M, Edimiris P, Mach P, Kubista M, Sjoback R, Rohlova E . Gene Expression Signatures in Circulating Tumor Cells Correlate with Response to Therapy in Metastatic Breast Cancer. Clin Chem. 2017; 63(10):1585-1593. DOI: 10.1373/clinchem.2016.269605. View

Obermayr E, Maritschnegg E, Agreiter C, Pecha N, Speiser P, Helmy-Bader S . Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells. Oncotarget. 2018; 9(1):812-823. PMC: 5787513. DOI: 10.18632/oncotarget.22549. View

Miyamoto D, Lee R, Kalinich M, LiCausi J, Zheng Y, Chen T . An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discov. 2018; 8(3):288-303. PMC: 6342192. DOI: 10.1158/2159-8290.CD-16-1406. View

Singhal U, Wang Y, Henderson J, Niknafs Y, Qiao Y, Gursky A . Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res. 2018; 16(4):643-654. PMC: 5882567. DOI: 10.1158/1541-7786.MCR-17-0539. View

Wang Z, Spaulding B, Sienko A, Liang Y, Li H, Nielsen G . Mammaglobin, a valuable diagnostic marker for metastatic breast carcinoma. Int J Clin Exp Pathol. 2009; 2(4):384-9. PMC: 2615595. View

Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M . Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Clin Cancer Res. 2008; 14(9):2593-600. DOI: 10.1158/1078-0432.CCR-07-4758. View

10.

Obermayr E, Sanchez-Cabo F, Tea M, Singer C, Krainer M, Fischer M . Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer. 2010; 10:666. PMC: 3013085. DOI: 10.1186/1471-2407-10-666. View

11.

Deutsch T, Stefanovic S, Feisst M, Fischer C, Riedel F, Fremd C . Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer. Cancers (Basel). 2020; 12(4). PMC: 7226373. DOI: 10.3390/cancers12041055. View

12.

Ring A, Campo D, Porras T, Kaur P, Forte V, Tripathy D . Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer. Ann Surg Oncol. 2022; 29(5):2882-2894. PMC: 8989945. DOI: 10.1245/s10434-021-11135-2. View

13.

Bredemeier M, Edimiris P, Tewes M, Mach P, Aktas B, Schellbach D . Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment. Oncotarget. 2016; 7(27):41677-41690. PMC: 5173087. DOI: 10.18632/oncotarget.9528. View

14.

Strati A, Nikolaou M, Georgoulias V, Lianidou E . RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer. Diagnostics (Basel). 2021; 11(3). PMC: 7998407. DOI: 10.3390/diagnostics11030513. View

15.

Sim J, Wright C . The kappa statistic in reliability studies: use, interpretation, and sample size requirements. Phys Ther. 2005; 85(3):257-68. View

16.

Thery L, Meddis A, Cabel L, Proudhon C, Latouche A, Pierga J . Circulating Tumor Cells in Early Breast Cancer. JNCI Cancer Spectr. 2019; 3(2):pkz026. PMC: 6649836. DOI: 10.1093/jncics/pkz026. View

17.

Janni W, Rack B, Terstappen L, Pierga J, Taran F, Fehm T . Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clin Cancer Res. 2016; 22(10):2583-93. DOI: 10.1158/1078-0432.CCR-15-1603. View

18.

Van der Auwera I, Peeters D, Benoy I, Elst H, Van Laere S, Prove A . Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer. Br J Cancer. 2009; 102(2):276-84. PMC: 2816650. DOI: 10.1038/sj.bjc.6605472. View

19.

Hvichia G, Parveen Z, Wagner C, Janning M, Quidde J, Stein A . A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells. Int J Cancer. 2016; 138(12):2894-904. PMC: 5069649. DOI: 10.1002/ijc.30007. View

20.

Keup C, Mach P, Aktas B, Tewes M, Kolberg H, Hauch S . RNA Profiles of Circulating Tumor Cells and Extracellular Vesicles for Therapy Stratification of Metastatic Breast Cancer Patients. Clin Chem. 2018; 64(7):1054-1062. DOI: 10.1373/clinchem.2017.283531. View